marcu
w
butler
michael
p
kean
usa
approxim
adult
selfreport
experi
attack
acut
bronchiti
given
year
person
seek
medic
attent
us
physician
report
acut
bronchiti
ninth
common
ill
among
outpati
compar
annual
incid
rate
among
previous
well
adult
demonstr
unit
kingdom
prospect
studi
major
pathogen
implic
caus
acut
bronchiti
virus
pathogen
document
minor
patient
studi
date
hand
virus
even
fewer
bacteria
recogn
caus
acut
bronchiti
tabl
despit
laboratori
isol
typic
communityacquir
pneumonia
bacteria
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
investig
case
acut
bronchiti
one
studi
convinc
causat
data
show
bronchial
wall
invas
typic
bacteria
contrast
influenza
viral
infect
larg
airway
result
rapid
cytopatholog
chang
lymphocyt
inflammatori
infiltr
associ
denud
airway
epitheli
barrier
human
parainfluenza
virus
immunocompet
subject
caus
selflimit
respiratori
diseas
exhibit
tropism
toward
superfici
ciliat
cell
bud
virion
direct
apic
epitheli
surfac
human
parainfluenza
viru
infect
also
lead
inhibit
ciliari
motil
plausibl
contribut
impair
clearanc
mucu
cellular
debri
respiratori
syncyti
viru
resembl
parainfluenza
viru
limit
cytopath
potenti
human
airway
epithelium
target
superfici
ciliat
cell
result
impair
ciliari
beat
minim
discern
epitheli
necrosi
slough
occur
human
rhinovirusmedi
acut
bronchiti
symptom
thought
reflect
activ
host
defens
inflammatori
respons
less
cytopath
respiratori
virus
interestingli
vitro
evid
suggest
greater
suscept
rhinoviru
infect
bronchial
rather
nasal
epithelium
though
rhinoviru
preval
caus
upper
respiratori
lower
respiratori
tract
infect
bacteri
pathogen
best
describ
caus
acut
bronchiti
symptom
bordetella
pertussi
adher
ciliat
respiratori
epitheli
cell
induc
local
tissu
damag
via
tracheal
cytotoxin
dermonecrot
toxin
adenyl
cyclas
among
biolog
activ
substanc
virul
factor
anoth
caus
bacteria
mycoplasma
pneumonia
produc
adher
protein
particular
affin
respiratori
tract
epithelium
subsequ
attach
bacteria
releas
hydrogen
peroxid
superoxid
vacuol
cytotoxin
toxic
ciliat
epitheli
cell
approach
diagnosi
cardin
symptom
acut
bronchiti
acut
cough
present
day
usual
associ
purul
sputum
often
associ
wheez
chest
heavi
definit
acut
bronchiti
primari
diagnosi
secondari
underli
chronic
pulmonari
diseas
asthma
fever
gener
lowgrad
sever
paroxysm
cough
without
coughinduc
emesi
prolong
cours
prompt
consider
pertussi
infect
requir
high
index
suspicion
make
diagnosi
bronchiti
broadest
sens
refer
inflammatori
process
involv
bronchi
larg
conduct
airway
lung
distal
trachea
proxim
smaller
airway
bronchiol
latter
character
histolog
lack
hyalin
cartilag
goblet
cell
submucos
gland
bronchiti
classifi
acut
chronic
chronic
bronchiti
frequent
featur
chronic
obstruct
pulmonari
diseas
copd
convent
defin
product
excess
sputum
day
least
month
least
consecut
year
unlik
acut
bronchiti
princip
caus
insult
chronic
bronchiti
felt
aberr
respons
noxiou
stimuli
princip
tobacco
smoke
much
lesser
extent
air
pollut
occup
exposur
varieti
mainli
viral
also
bacteri
pathogen
respons
acut
exacerb
chronic
bronchitiscopd
noninfect
event
also
give
rise
exacerb
copd
includ
pulmonari
thrombo
embol
copd
role
antimicrobi
therapi
discuss
elsewher
textbook
see
practic
point
acut
bronchiti
constitut
one
wide
encount
condit
seen
clinician
typic
case
acut
bronchiti
tracheobronchi
tree
inflam
due
lower
respiratori
tract
infect
sever
pneumonia
infecti
agent
viral
origin
great
major
case
condit
present
cough
without
accompani
sputum
product
fail
settl
day
distinguish
overlap
common
cold
symptom
acut
bronchiti
persist
beyond
week
time
diagnos
consid
acut
bronchiti
common
usual
viral
infect
last
week
usual
requir
test
antimicrobi
therapi
nonetheless
inappropri
overprescript
antibiot
acut
bronchiti
remain
global
concern
bronchiectasi
increasingli
recogn
etiolog
heterogen
potenti
seriou
form
chronic
suppur
lung
infect
tendenc
recurr
infect
exacerb
declin
health
statu
time
bronchiectat
lung
exhibit
divers
polymicrobi
commun
phase
clinic
stabil
exacerb
interact
defect
host
defens
impair
drainag
obstruct
perpetu
lung
inflamm
via
activ
immun
proteolyt
oxid
process
therapi
stabl
bronchiectasi
center
airway
secret
clearanc
strategi
approach
design
prevent
acut
exacerb
mainli
antibioticand
immunizationbas
target
identifi
pathogen
grow
bodi
research
activ
focus
noncyst
fibrosi
bronchiectasi
intervent
includ
emphasi
accur
etiolog
diagnosi
use
clinic
predict
tool
inhal
antibiot
longterm
macrolid
favor
influenc
diseas
outcom
necessari
perform
diagnost
test
clinic
suspicion
acut
bronchiti
erron
assum
presenc
purul
sputum
indic
seriou
infect
though
fewer
patient
discolor
sputum
evid
pneumonia
practic
diagnost
difficulti
provid
rational
find
tool
may
predict
bacteri
rather
viral
infect
procalcitonin
pct
peptid
prehormon
calcitonin
normal
secret
c
cell
thyroid
respons
hypercalcemia
low
level
serum
ngml
also
elabor
inflammatori
state
produc
liver
hepatocyt
peripher
blood
mononuclear
cell
modul
lipopolysaccharid
sepsisrel
chemokin
signal
upregul
appear
abrog
interferongammamedi
inhibit
set
viral
infect
render
pct
specif
bacteri
infect
recent
metaanalysi
random
trial
particip
mainli
europ
examin
whether
procalcitonin
level
could
use
safe
guid
therapi
decis
set
vari
primari
care
icu
conclud
strategi
associ
higher
mortal
rate
treatment
failur
significantli
reduc
antibiot
consumpt
across
clinic
set
type
acut
respiratori
tract
infect
signific
minor
studi
acut
bronchiti
recent
multin
reallif
observ
studi
show
acut
bronchiti
patient
highest
complianc
pctguid
antibiotictreat
algorithm
lower
respiratori
tract
infect
vs
acut
exacerb
copd
vs
communityacquir
pneumonia
p
overal
studi
encourag
use
highli
sensit
immunoassay
pct
measur
found
antibiot
therapi
durat
shorter
pct
algorithm
compli
data
encourag
use
pct
routin
care
await
valid
larg
trial
influenzalik
ill
rapid
influenza
diagnosi
test
avail
use
season
us
center
diseas
control
cdc
issu
guidanc
use
test
clinic
practic
bacteri
cultur
sputum
recommend
patient
acut
bronchiti
pertussi
diagnos
nasopharyng
swab
aspir
taken
posterior
nasopharynx
sent
cultur
supplement
rapid
polymeras
chain
reaction
pcr
test
avail
given
rapid
sensit
latter
test
differenti
diagnosi
acut
bronchiti
includ
caus
gener
case
acut
bronchiti
manag
conserv
symptomat
support
advic
knowledg
healthcar
profession
vast
major
case
acut
bronchiti
bacteri
origin
selflimit
wellfound
concern
overprescript
antibiot
acut
bronchiti
could
lead
excess
advers
drug
reaction
cost
antimicrobi
resist
recent
cochran
systemat
review
antibiot
therapi
data
random
control
trial
involv
instanc
acut
respiratori
tract
infect
treatment
strategi
result
least
antibiot
use
compar
patientrel
outcom
avoid
prescrib
antibiot
advis
patient
return
symptom
resolv
suggest
antiinflammatori
therapi
might
reduc
cough
symptom
acut
bronchiti
recent
spanish
primari
care
studi
subject
random
receiv
nonsteroid
antiinflammatori
drug
ibuprofen
amoxicillinclavulan
acid
placebo
uncompl
acut
bronchiti
discolor
sputum
show
signific
differ
number
day
cough
ibuprofen
day
ci
amoxicillinclavulan
day
ci
placebo
day
ci
appropri
symptomat
treatment
acut
bronchiti
includ
consider
shortact
agonist
promin
wheez
dyspnea
exert
although
conflict
limit
data
approach
expert
differ
whether
antituss
agent
shortterm
codein
prepar
contain
hydrocodon
use
persist
cough
greater
consensu
surround
recommend
macrolid
therapi
b
pertussi
caus
oseltamivir
zanamivir
influenza
identifi
earli
cours
ill
ectasia
dilat
bronchi
refer
bronchiectasi
uncommon
suppur
lung
diseas
state
typic
character
chapter
bronchiti
bronchiectasi
appear
elev
mortal
rate
observ
prospect
studi
bronchiectasi
suffer
studi
enrol
follow
patient
bronchiectasi
period
year
mortal
rate
observ
recent
bronchiectasi
cohort
patient
mortal
rate
period
pathophysiolog
varieti
factor
usual
involv
develop
bronchiectasi
typic
defect
host
defens
form
impair
drainag
andor
obstruct
within
airway
wall
combin
perpetu
infecti
process
beget
inflamm
activ
immun
respons
proteolyt
oxid
process
divers
array
condit
associ
develop
bronchiectasi
vari
extent
sever
see
tabl
exampl
recogn
etiolog
shown
figur
howev
despit
exhaust
workup
may
caus
found
half
case
envisag
import
advanc
understand
pathobiolog
noncyst
fibrosi
cf
bronchiectasi
result
collabor
form
patient
registri
establish
cough
product
purul
sputum
predisposit
recurr
often
refractori
acut
infect
exacerb
often
associ
progress
dyspnea
acceler
declin
lung
function
episod
hemoptysi
impair
qualiti
life
differ
morpholog
pattern
ectat
airway
describ
includ
cylindr
varicoid
visual
resembl
venou
varicos
saccular
cystic
varieti
latter
two
signifi
sever
destruct
diseas
typic
though
uncommon
diseas
bronchiectasi
appear
increasingli
recogn
base
recent
medicar
part
b
outpati
data
averag
annual
preval
rate
peopl
previou
studi
show
estim
preval
adult
bronchiectasi
usa
data
suggest
higher
preval
found
asian
popul
among
women
advanc
age
annual
associ
cost
care
usa
estim
million
germani
steadili
increas
preval
bronchiectasisassoci
hospit
recent
observ
highest
elderli
femal
averag
annual
ageadjust
rate
bronchiectasi
primari
diagnosi
hospit
per
asian
data
suggest
even
higher
rate
annual
ageadjust
hospit
diagnosi
bronchiectasi
per
airway
infect
promin
featur
bronchiectasi
relationship
infect
diseas
progress
imperfectli
understood
tradit
cultur
techniqu
long
identifi
aerob
pathogen
h
influenza
pseudomona
aeruginosa
strep
pneumonia
work
tunney
colleagu
use
addit
anaerob
cultur
highthroughput
pyrosequenc
sputum
sampl
demonstr
divers
polymicrobi
commun
bronchiectat
lung
clinic
stabil
exacerb
unexpect
degre
stabil
observ
microbi
load
commun
composit
studi
author
contend
chang
microbiota
composit
account
exacerb
bronchiectasi
conced
potenti
pathobiolog
interact
among
microb
alter
microbi
genet
factor
remain
unexplor
potenti
mechan
exacerb
other
shown
clinic
measur
bronchiectat
diseas
activ
relat
lower
airway
microbiota
roger
cowork
show
divers
lower
airway
microbiota
noncf
bronchiectasi
higher
forc
expiratori
volum
second
fev
like
reflect
less
overgrowth
pathogen
p
aeruginosa
group
also
show
bacteri
commun
composit
similar
correl
significantli
neutrophil
inflamm
coughspecif
symptom
lung
function
recent
purcel
et
al
uk
evalu
sputa
noncf
bronchiectasi
outpati
cultur
pyrosequenc
found
relationship
bacteri
commun
divers
lung
function
antibiot
therapi
gender
though
found
p
aeruginosa
h
influenza
exert
signific
effect
divers
bacteri
commun
lung
patient
larger
number
taxa
includ
pasteurellacea
streptococcacea
xanthomonadacea
burkholderial
prevotellacea
veillonellacea
associ
acut
exacerb
wherea
smaller
number
taxa
includ
pseudomona
spp
correl
stabl
state
suggest
bacteri
commun
lung
exacerb
patient
dynam
commun
composit
seen
stabl
patient
somewhat
odd
earlier
find
tunney
et
al
use
similar
pyrosequenc
technolog
recent
studi
evalu
stabil
signal
differ
timepoint
howev
nontubercul
mycobacteria
ntm
appear
uncommonli
identifi
noncf
bronchiectasi
detect
patient
one
cohort
predilect
toward
mycobacterium
avium
complex
mac
anoth
larg
cohort
studi
adultonset
bronchiectasi
patient
identifi
ntm
key
factor
high
frequenc
colon
p
aeruginosa
cf
noncf
bronchiectasi
abil
form
biofilm
protect
bacteri
coloni
innat
host
respons
effect
antibacteri
therapi
mani
bacteria
caus
bronchiectasi
eg
pseudomona
aeruginosa
form
biofilm
bronchiectasi
may
present
patient
present
chronic
cough
sputum
expector
usual
histori
frequent
attack
chest
infect
requir
repeat
cours
antibiot
less
commonli
cough
may
nonproduct
frequent
report
symptom
includ
dyspnea
pleurit
chest
pain
wheez
symptom
rhinosinus
patient
may
also
episod
hemoptysi
fatigu
women
stress
urinari
incontin
suspect
present
includ
patient
ostens
diagnosi
copd
lack
convinc
risk
factor
smoke
patient
difficult
control
asthma
despit
optim
manag
find
pseudomona
ntm
sputum
suspicion
bronchiectasi
aris
diagnost
test
conduct
firstli
confirm
find
bronchiectasi
radiolog
assess
revers
etiolog
factor
final
physiolog
assess
appropri
baselin
indic
function
capac
patient
view
followup
optim
test
make
diagnosi
high
resolut
comput
tomographi
ct
scan
imag
prefer
use
helic
highresolut
multidetector
technolog
usual
avail
look
evid
airway
dilat
mucu
plug
dilat
airway
suggest
lack
bronchial
taper
see
figur
presenc
ring
shadow
sometim
accompani
mucussecret
signet
ring
sign
crosssect
lumin
airway
diamet
greater
diamet
adjac
vessel
see
figur
dilat
airway
reproduc
suggest
bronchiectasi
lumen
least
time
diamet
accompani
vessel
mucu
plug
involv
larg
andor
small
airway
latter
site
result
appear
known
treeinbud
see
figur
studi
frequent
undertaken
evalu
bronchiectasi
patient
includ
complet
blood
count
may
show
anemia
suggest
ulcer
coliti
crohn
diseas
may
suggest
eosinophil
state
bacteri
mycobacteri
fungal
sputum
stainscultur
serum
immunoglobulin
e
g
igg
subclass
pneumococc
vaccin
titer
look
impair
respons
serum
though
multipl
caus
exist
bronchiectasi
manag
diseas
offic
set
larg
center
principl
airway
clearanc
strategi
includ
exercisebas
intervent
approach
design
prevent
acut
exacerb
mainli
antibioticbas
target
identifi
pathogen
also
immun
less
clear
role
bronchodil
addit
antiinflammatori
therapi
present
therapeut
intervent
intend
enhanc
qualiti
life
preserv
pulmonari
function
minim
healthcar
util
inher
difficulti
produc
robust
evid
therapeut
efficaci
safeti
divers
patient
popul
yet
pharmaceut
agent
receiv
approv
us
food
drug
administr
treatment
noncf
bronchiectasi
signific
progress
made
howev
condit
attract
greater
attent
past
import
direct
therapi
underli
caus
bronchiectasi
known
appropri
acut
manag
base
identifi
need
inpati
therapi
refin
antibiot
select
reflect
isol
pathogen
local
resist
pattern
augment
airway
clearanc
techniqu
deal
specif
situat
includ
hemoptysi
need
surgic
intervent
lung
transplant
surgeri
remov
sever
damag
segment
lobe
perpetu
infect
hemorrhag
continu
reced
earlier
identif
better
medic
manag
recent
year
data
begun
accru
specif
address
noncf
bronchiectasi
manag
import
lesson
learnt
exampl
potenti
danger
cf
therapi
indiscrimin
extrapol
noncf
patient
aerosol
recombin
deoxyribonucleas
dornasealpha
exacerb
bronchiectasi
difficult
identifi
copd
asthma
bronchiectasi
patient
often
feel
tire
prone
breathless
describ
discolor
sputum
baselin
though
univers
agre
definit
bronchiectasi
exacerb
highqual
clinic
trial
util
electrophoresi
sweat
chlorid
measur
two
separ
occas
cftr
genet
test
alpha
antitrypsin
level
phenotyp
genotyp
serolog
test
antinuclear
antibodi
rheumatoid
factor
anticycl
citrullin
peptid
ssaro
ssbla
antibodi
less
frequent
request
test
reserv
specif
situat
includ
outlin
tabl
spirometri
use
assess
airway
diseas
howev
forc
expiratori
volum
air
second
fev
limit
decisionmak
tool
bronchiectasi
poor
correl
ct
imag
expiratori
airflow
limit
dynam
chang
fev
respons
therapi
modest
sever
bronchiectasi
may
better
assess
use
bronchiectasi
sever
index
bsi
prospect
valid
multidimension
clinic
predict
tool
exacerb
preced
year
erythromycin
shown
modestli
reduc
protocoldefin
pulmonari
exacerb
mean
event
vs
per
patient
per
year
p
reduc
sputum
product
attenu
declin
lung
function
mean
differ
fev
predict
p
cost
increas
macrolideresist
oropharyng
streptococci
median
chang
vs
placebo
subject
p
pseudomonascolon
patient
also
gain
fewer
exacerb
activ
treatment
arm
recent
multicent
random
trial
eman
netherland
bat
trial
evalu
month
daili
azithromycin
mg
versu
placebo
bronchiectasi
patient
least
three
lower
respiratori
tract
infect
previou
year
macrolid
resist
note
azithromycin
placebo
activ
therapi
group
experienc
fewer
exacerb
p
least
one
exacerb
occur
azithromycintr
subject
versu
placebo
hazard
ratio
ci
embrac
trial
enrol
least
one
exacerb
bronchiectasi
previou
year
found
month
threetimesaweek
azithromycin
mg
reduc
exacerb
frequenc
rate
compar
placebo
rel
reduct
ci
though
without
benefit
term
lung
function
qualiti
life
shorter
studi
consensu
may
slowli
emerg
regard
benefit
macrolid
therapi
patient
experienc
frequent
exacerb
noncf
bronchiectasi
though
mani
question
remain
includ
frequenc
dose
select
appropri
patient
import
macrolid
resist
cardiovascular
toxic
patient
popul
widespread
macrolid
use
occur
toxic
macrolid
also
requir
consider
weigh
decis
commenc
longterm
macrolid
therapi
includ
hear
loss
diarrhea
abdomin
discomfort
nausea
hepatotox
therapi
longterm
macrolid
perhap
reconsid
manag
reason
well
aspect
bronchiectasi
manag
includ
airway
clearanc
prompt
use
antibiot
exacerb
show
evid
progress
diseas
lack
sever
baselin
impair
lung
function
number
clinic
trial
year
random
control
evalu
prolong
treatment
variou
nebul
antibiot
noncf
bronchiectasi
includ
amoxicillin
ceftazidim
aztreonam
colistin
ciprofloxacin
aminoglycosid
agent
chiefli
gentamicin
tobramycin
trial
thu
far
suffer
vari
degre
underpow
studi
design
limit
includ
insuffici
long
durat
activ
therapi
reproduc
limit
often
observ
diseas
popul
character
phenotyp
heterogen
factor
noncf
bronchiectasi
promis
indic
nonetheless
inhal
gentamicin
use
offlabel
noncf
bronchiectasi
reconstitut
mg
intraven
prepar
salin
ml
volum
employ
commonli
use
nebul
system
given
twicedaili
regimen
therapi
shown
day
reduc
microbi
load
sputum
myeloperoxidas
surrog
neutrophil
quantiti
sputum
volum
improv
peak
expiratori
flow
rate
improv
exercis
capac
assess
borg
breathless
score
walk
test
distanc
recent
singlemask
studi
random
patient
year
either
nebul
gentamicin
nebul
normal
salin
found
gentamicin
therapi
led
reduct
sputum
bacteri
densiti
secondari
endpoint
exacerb
frequenc
also
favor
gentamicin
placebo
iqr
vs
igr
p
though
outcom
measur
revert
baselin
followup
attest
lack
durabl
respons
therapi
regard
inhal
tobramycin
solut
tsi
studi
aerosol
tobramycin
mg
bd
vs
placebo
equival
popul
patient
colon
pseudomona
report
reduct
pseudomon
densiti
treatment
effect
seen
lung
function
concern
toxic
exacerb
frequenc
primari
outcom
show
similar
definit
exacerb
use
see
tabl
studi
describ
symptombas
exacerb
increas
new
onset
one
three
anthonisen
criteria
use
describ
copd
exacerb
increas
sputum
volum
sputum
purul
dyspnea
british
thorac
societi
recent
recommend
antibiot
given
noncf
bronchiectasi
exacerb
present
acut
deterior
typic
cours
number
day
worsen
pulmonari
symptom
andor
system
upset
pulmonari
symptom
cough
increas
sputum
volum
chang
viscos
increas
sputum
purul
without
increas
wheez
breathless
hemoptysi
intuit
attract
aim
suppress
bacteri
burden
symptomat
patient
bronchiectasi
fail
measur
pathogen
organ
erad
p
aeruginosa
first
identifi
sputum
recommend
erad
attempt
cours
oral
antipseudomon
agent
ciprofloxacin
mg
bd
regimen
consider
fail
clear
organ
intraven
inhal
antipseudomon
patient
continu
copiou
sputum
frequent
infect
episod
consid
prolong
antibiot
therapi
support
approach
clear
proport
relationship
airway
bacteri
load
one
hand
measur
system
airway
inflamm
exacerb
healthrel
qualiti
life
inflamm
lessen
shortand
longterm
antibiot
intervent
longterm
oral
antibiot
clinic
use
studi
intervent
bronchiectasi
patient
decad
systemat
cochran
review
nine
elig
trial
conclud
small
benefit
use
prolong
antibiot
treat
purul
bronchiectasi
children
adult
nonmacrolid
oral
antibiot
concern
amoxicillin
doxycyclin
would
seem
reason
consid
prolong
suppress
regimen
patient
suffer
least
three
exacerb
year
consid
longterm
macrolid
regimen
provid
colon
p
aeruginosa
nontubercul
mycobacteria
problemat
pathogen
present
treat
macrolid
monotherapi
rather
accord
american
thorac
societyinfecti
diseas
societi
america
guidelin
macrolid
antibiot
continu
attract
increas
attent
prevent
intervent
bronchiectasi
australian
bless
trial
random
noncf
bronchiectasi
patient
receiv
either
twice
daili
erythromycin
ethylsuccin
mg
bd
per
os
placebo
one
year
singl
center
patient
two
altenburg
et
al
fall
least
either
forc
expiratori
volum
second
fev
forc
vital
capac
fvc
previous
record
valu
receiv
dose
inhal
agonist
medic
simultan
use
patient
lesser
extent
bronchospasm
would
otherwis
benefit
inhal
antibiot
patient
bronchiectasi
experi
symptom
acut
exacerb
see
tabl
sputum
sent
bacteri
mycobacteri
stain
cultur
antibiot
therapi
initi
pend
result
sampl
base
patient
prior
sputum
result
known
avail
prior
bacteriolog
inform
patient
sputum
empir
therapi
direct
pseudomona
cogniz
frequent
isol
pathogen
includ
h
influenza
catarrhali
staphylococcu
aureu
quinolon
levofloxacin
moxifloxacin
would
appropri
choic
given
broader
spectrum
activ
quinolon
compar
ciprofloxacin
provid
patient
counsel
regard
risk
quinoloneassoci
tendinopathi
especi
older
renal
impair
patient
concomit
steroid
clostridium
difficil
coliti
anoth
concern
mani
antibiot
especi
elderli
chest
radiograph
help
rule
noninfect
caus
exacerb
pneumonia
less
commonli
pneumothorax
major
patient
experienc
exacerb
treat
outpati
set
sputum
result
known
therapi
tailor
reflect
sensit
result
aim
optimum
balanc
among
efficaci
toxic
mani
patient
bronchiectasi
resist
strain
bacteria
p
aeruginosa
oral
activ
form
therapi
intraven
therapi
requir
may
provid
inpati
outpati
basi
latter
patient
satisfi
local
servic
criteria
admiss
hospit
advis
patient
display
signific
tachypnea
hypotens
confus
hypoxemia
fever
british
thorac
societi
guidelin
make
expert
recommend
combin
antibiot
set
resist
pseudomona
acknowledg
issu
controversi
may
prefer
decid
singl
versu
combin
therapi
base
overal
initi
sever
present
though
firm
data
either
approach
lack
aminoglycosid
use
addit
anoth
agent
monotherapi
requir
protocol
monitor
pharmaci
involv
aim
peak
concentr
mgl
trough
concentr
mgl
presenc
renal
impair
advanc
patient
age
typic
lengthi
durat
antibiot
given
bronchiectasi
exacerb
highlight
need
particular
vigil
toxic
receiv
aminoglycosid
acut
bronchiti
noncyst
fibrosi
bronchiectasi
reflect
oppos
end
spectra
chronic
incid
sever
infecti
airway
diseas
tradit
suffer
dearth
research
focu
acut
bronchiti
gener
viral
mediat
repres
opportun
healthcar
profess
make
favor
impact
emerg
epidem
antimicrobi
resist
though
influenza
need
care
consid
late
heighten
interest
noncyst
fibrosi
bronchiectasi
particular
stem
increas
rate
detect
better
understand
underli
pathobiolog
unmet
clinic
need
proven
licens
therapi
diseas
character
pulmonari
infect
episod
role
innat
adapt
immun
respons
interact
host
immun
local
microbiom
continu
major
focu
interest
utilis
newer
research
technolog
analog
recent
research
direct
complex
disord
research
prioriti
bronchiectasi
recent
articul
newli
form
bronchiectasi
network
uk
center
need
better
epidemiolog
data
enhanc
effort
help
identifi
caus
bronchiectasi
patient
potenti
revers
caus
factor
identifi
inhal
tobramycin
small
uncontrol
pilot
studi
patient
given
tsi
week
week
week
total
patient
experienc
therapylimit
side
effect
cough
wheez
worsen
dyspnea
higher
rate
wheez
tsitreat
subject
vs
aerosol
quininesulph
placebo
arm
seen
anoth
trial
day
tsi
ad
oral
ciprofloxacin
acut
exacerb
p
aeruginosa
infect
noncf
bronchiectasi
despit
favor
effect
tobramycin
microbiolog
paramet
nebul
colistin
wide
use
europ
treat
noncf
bronchiectasi
data
support
use
small
australian
observ
studi
nebul
colistin
mg
daili
ml
solut
ad
usual
care
patient
p
aeruginosa
show
slower
declin
fev
mlyear
vs
ml
year
p
improv
qualiti
life
recent
multin
doubleblind
random
control
trial
evalu
ineb
adapt
aerosol
deliveri
devic
philip
respiron
chichest
uk
noncf
bronchiectasi
patient
colon
p
aeruginosa
treat
colistin
million
iu
vs
salin
placebo
primari
endpoint
time
first
exacerb
met
studi
median
time
quartil
exacerb
vs
day
colistin
placebo
group
respect
p
secondari
endpoint
encourag
improv
time
exacerb
adher
patient
adher
quartil
reduc
p
aeruginosa
densiti
improv
qualiti
life
score
treatmentinduc
wheez
rate
colistintr
subject
versu
control
advers
event
significantli
differ
notabl
fewer
patient
receiv
azithromycin
therapi
highlight
gap
knowledg
regard
role
inhal
antibiot
chronic
macrolid
user
monobactam
aztreonam
unaccept
airway
side
effect
use
pure
form
airway
inflammatori
chang
aztreonam
inhal
result
develop
lyophil
formul
use
lysin
excipi
use
treat
pseudomonascolon
cystic
fibrosi
patient
recent
preliminari
data
two
phase
iii
trial
combin
total
patient
assign
aztreonam
lysin
inhal
azli
day
demonstr
failur
meet
primari
endpoint
improv
qualiti
life
score
advers
event
note
activ
drug
arm
trial
though
trial
less
favor
treatment
effect
excess
eversmok
among
azlitr
group
vs
possibl
confound
influenc
longact
formul
ciprofloxacin
contain
mixtur
free
drug
liposom
ciprofloxacin
develop
attempt
reduc
allpervas
side
effect
bronchospasm
phase
ii
multicent
trial
noncf
bronchiectasi
patient
random
either
dualreleas
ciprofloxacin
inhal
drcfi
control
liposom
salin
treat
week
day
day
manner
drcfi
result
signific
reduct
pseudomona
densiti
delay
time
first
exacerb
median
vs
day
p
modifi
intent
treat
analysi
p
per
protocol
analysi
fewer
pulmonari
advers
effect
versu
placebo
relat
inhal
antibiot
nontubercul
mycobacteria
complic
bronchiectasi
retrospect
analysi
patient
noncf
bronchiectasi
cf
inhal
amikacin
ad
fail
regimen
ntm
found
symptom
score
either
improv
stabil
major
subject
though
worsen
ct
appear
median
month
followup
fifteen
patient
cultureposit
mycobacterium
abscessu
remain
mac
thirtyf
per
cent
cohort
stop
amikacin
due
toxic
therapi
irrespect
choic
inhal
antibiot
noncf
bronchiectasi
patient
view
potenti
druginduc
wheez
initi
treatment
best
administ
clinic
set
spirometri
perform
preand
minut
postdos
order
detect
patient
whose
fev
measur
drop
significantli
respons
inhal
antibiot
ie
drop
fev
ml
hope
live
bronchiectasi
period
past
